# Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose Administration

> **NCT02980458** · PHASE1 · COMPLETED · sponsor: **SocraTec R&D GmbH** · enrollment: 25 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Deferiprone 500Mg Tablet
- **DRUG:** Deferiprone 500 MG Oral Tablet [Ferriprox]

## Key facts

- **NCT ID:** NCT02980458
- **Lead sponsor:** SocraTec R&D GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2016-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02980458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02980458, "Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose Administration". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02980458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*